Tegaserod in constipation associated with Parkinson disease

John Christopher Morgan, Kapil Dev Sethi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalClinical Neuropharmacology
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Constipation
Parkinson Disease
Gastrointestinal Motility
Diet Therapy
Serotonin Receptor Agonists
Laxatives
tegaserod

Keywords

  • 5-HT agonist
  • Constipation
  • Parkinson disease
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Tegaserod in constipation associated with Parkinson disease. / Morgan, John Christopher; Sethi, Kapil Dev.

In: Clinical Neuropharmacology, Vol. 30, No. 1, 01.01.2007, p. 52-54.

Research output: Contribution to journalArticle

@article{94917b9ad67048b99dc36bb6b75061d9,
title = "Tegaserod in constipation associated with Parkinson disease",
abstract = "Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.",
keywords = "5-HT agonist, Constipation, Parkinson disease, Tegaserod",
author = "Morgan, {John Christopher} and Sethi, {Kapil Dev}",
year = "2007",
month = "1",
day = "1",
doi = "10.1097/01.WNF.0000240942.21499.97",
language = "English (US)",
volume = "30",
pages = "52--54",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Tegaserod in constipation associated with Parkinson disease

AU - Morgan, John Christopher

AU - Sethi, Kapil Dev

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

AB - Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

KW - 5-HT agonist

KW - Constipation

KW - Parkinson disease

KW - Tegaserod

UR - http://www.scopus.com/inward/record.url?scp=33846811509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846811509&partnerID=8YFLogxK

U2 - 10.1097/01.WNF.0000240942.21499.97

DO - 10.1097/01.WNF.0000240942.21499.97

M3 - Article

C2 - 17272971

AN - SCOPUS:33846811509

VL - 30

SP - 52

EP - 54

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -